Trial Profile
Phase 1/2 Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in Combination With Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer After Endocrine Failure
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Lerociclib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Adverse reactions; Proof of concept
- Sponsors G1 Therapeutics
- 07 Nov 2023 This trial has been discontinued in Bulgaria (End Date: 30 Oct 2023), according to European Clinical Trials Database record.
- 14 Feb 2023 Planned End Date changed from 1 Apr 2023 to 1 Oct 2023.
- 14 Feb 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Jun 2023.